Toggle navigation
Menu
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
73°
Search
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Local Weather
News
Sports
Entertainment
Calendar
Games
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Town & Gown
Subscribe
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Optinose Inc
(NQ:
OPTN
)
4.190
USD
-0.050 (-1.18%)
Official Closing Price
Updated: 4:23 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Optinose Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage
July 10, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ...
Tags
Top Stories
AKAO
ZGNX
From
Benzinga
OPTN: Insiders vs. Shorts
July 03, 2018
The most recent short interest data was recently released for the 06/15/2018 settlement date, and OptiNose Inc (OPTN) is one of the most shorted stocks of the Russell 3000, based on 5.65 "days to...
Tags
Stocks
From
Market News Video
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
July 02, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the...
From
GlobeNewswire News Releases
Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos
June 29, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ...
Tags
ARLZ
VRTX
CRIS
From
Benzinga
Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals
June 21, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that results of the Phase 3 NAVIGATE II trial and the...
From
GlobeNewswire News Releases
Insiders Seeing Green With OPTN At New 52-Week High
June 21, 2018
In trading on Thursday, shares of OptiNose Inc (OPTN) touched a new 52-week high of $25.76/share. That's a 71.62% rise, or $10.75 per share from the 52-week low of $15.01 set back on 11/14/2017..
Tags
Stocks
From
Market News Video
Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The Year 2018 in Greater
June 15, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller and President and Chief...
From
GlobeNewswire News Releases
Investors Grab OPTN Even Cheaper Than Its Secondary Stock Offering
June 12, 2018
Looking back to 6 days ago, OptiNose Inc (OPTN) priced a 5,000,000 share secondary stock offering at $22.25 per share. Buyers in that offering made a considerable investment into the company, expecting...
Tags
Stocks
From
Market News Video
Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares
June 11, 2018
OptiNose, Inc. (NASDAQ:OPTN), announced today the closing of its underwritten public offering of 5,750,000 of its common shares at a price to the public of $22.25 per common share, including 750,000...
From
GlobeNewswire News Releases
Optinose Announces Pricing of Public Offering of Common Stock
June 06, 2018
OptiNose, Inc. (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting...
From
GlobeNewswire News Releases
Optinose Announces Launch of Public Offering of Common Stock
June 04, 2018
OptiNose, Inc. (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public...
From
GlobeNewswire News Releases
Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings
May 16, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ...
Tags
SPHS
News
BIOL
From
Benzinga
Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights
May 14, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31,...
From
GlobeNewswire News Releases
Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018
May 07, 2018
Conference Call and Webcast Scheduled for Monday, May 14 at 8:00 a.m. Eastern Time
From
GlobeNewswire News Releases
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area
April 23, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller and President/COO Ramy Mahmoud,...
From
GlobeNewswire News Releases
Investors Should Opt Out Of OptiNose Before IPO Lock-Up Expires
April 04, 2018
When the 180-day lock-up period for OptiNose, Incorporated (OPTN) ends on April 11, 2018, the company's pre-IPO shareholders and insiders will have the ability to sell large blocks of...
Tags
Healthcare
Pharma/Biotech
Stocks / Equities
From
Blogs - TalkMarkets
Drug companies are beginning to wake up to this new risk factor
March 19, 2018
New programs that target coupons for expensive medications have taken off.
Tags
SNY
AT:UCB
Company Announcements
From
MarketWatch
Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania
March 15, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinose was named the Emerging Company of the...
From
GlobeNewswire News Releases
Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights
March 13, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended...
From
GlobeNewswire News Releases
Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018
March 06, 2018
Conference Call and Webcast Scheduled for Tuesday, March 13 at 8:00 a.m. Eastern Time
From
GlobeNewswire News Releases
Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress
February 26, 2018
Optinose expects to make XHANCE (fluticasone propionate) nasal spray 93mcg available through retail pharmacies in early April 2018
From
GlobeNewswire News Releases
Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee
February 22, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Sandra L. Helton as...
From
GlobeNewswire News Releases
Peter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania
February 20, 2018
Optinose Also Named as Finalist for Emerging Company of the Year
From
GlobeNewswire News Releases
Analysts See 10% Gains Ahead For IWV
February 16, 2018
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
OptiNose Becomes Oversold (OPTN)
February 15, 2018
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Tags
Stocks
From
Market News Video
Optinose to Present at the 2018 RBC Capital Markets Healthcare Conference
February 15, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will...
From
GlobeNewswire News Releases
Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference
February 09, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will...
From
GlobeNewswire News Releases
Optinose Announces $100 Million Debt Financing from Athyrium Capital Management
January 02, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a $100 million debt...
From
GlobeNewswire News Releases
40 Biggest Movers From Yesterday
December 12, 2017
Gainers Proteostasis Therapeutics Inc (NASDAQ: PTI) shares climbed 161.28 percent to close at $6.14 on Tuesday after the ...
Tags
OMED
SYRS
NCS
From
Benzinga
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
December 11, 2017
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the...
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.